Hyung makes sense of what consumers want
Home
Our news
GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations
Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US
Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD
Corporate reporting
Reporting on our relationships
@GSKUS Twitter Feed
Latest tweets
-
“Be flexible—most career paths are not linear.” On #AmericanBusinessWomensDay our colleagues share their career and… twitter.com/i/web/status/9…
2 days ago
-
“Play to your strengths & don’t be afraid to take risks w/ your career.” Our GSK women share their career advice… twitter.com/i/web/status/9…
2 days ago
-
Welcome 2017 #PennWomen sponsor GSK! GSK’s Angela Steel, VP, clinical operations, infectious diseases, speaks on... fb.me/6tUY66Ub2
3 days ago
-
Learn about our commitment to developing innovative therapies & working to meet the needs of ALL #COPD patients… twitter.com/i/web/status/9…
3 days ago
Working at GSK
GSK careers
Looking for a new job? Find out about working at GSK and how to apply for a job.